Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Tumor-Treg-Targeting

Financiado

Cerrado

Training Network for the education of the next generation scientist in targeting...

Training Network for the education of the next generation scientist in targeting the supressive capacity of regulatory T cells specifically within tumours Tumour immune-therapy has made dramatic improvements in recent years, saving the lives of cancer patients who just a few years ago would have been considered untreatable. It thereby became apparent that one specific type of immune... ver más

30/11/2022

UPNA

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

UNIVERSIDAD DE NAVARRA No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 849

Fecha límite participación Sin fecha límite de participación.

Ver 8 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-11-30

MSCA-ITN-2017: Innovative Training Networks

I+D

Cerrada hace 8 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

8 Participantes

UPNA

247.87K€ | Lider

Leiden University Medical Ce...

N.D. | Participante

FUNOACION PARA LA INVESTIG

247.87K€ | Participante

Proyectos interesantes

MiTE

Medical Technol...

Data Science

150K€ Cerrado

TNT-TUMORS

Medical Technol...

Data Science

2M€ Cerrado

CHEMCHECK

Medical Technol...

Data Science

2M€ Cerrado

SAF2013-42772-R

Medical Technol...

Data Science

121K€ Cerrado

CAR-T-uning

Medical Technol...

Data Science

150K€ Cerrado

NextGen IO

Medical Technol...

Data Science

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 63 meses Fecha Inicio: 2017-08-02
Fecha Fin: 2022-11-30

Líder del proyecto

UNIVERSIDAD DE NAVARRA No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 849

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Tumour immune-therapy has made dramatic improvements in recent years, saving the lives of cancer patients who just a few years ago would have been considered untreatable. It thereby became apparent that one specific type of immune cell, so called regulatory T-cells, critically hampers the efficacy of tumour immune-therapy. Tumours, however, attract and exploit the immune-regulatory function of Tregs to dampen local immune responses and to induce local tolerance. In recent years, inhibitors that directly target immune-suppressive mechanisms of T cells have found clinical application with great success. The clinical application of these so called check-point inhibitors, however, is accompanied by severe side effects in treated patients. Thus improvement of the efficacy of current immune-therapeutic treatments is a major unmet need. This proposal will employ the newest developments in antibody design to target the next generation of biologics right towards tumour-residential Tregs or directly into the tumour micro-environment itself. In this way we will be able to specifically shift the local immune suppressive environment within tumours, while leaving tissue homeostasis in noncancerous tissues unaffected, and thus diminish treatment associated side-effects. The here proposed project combines the expertise of fundamental immunologist, tumour immunologists and cell biologists with that of a life-science biotechnology company and that of experts in clinical cancer research to address this aspect. This group will lead a training network that aims at educating a new generation of researchers, who will be able to bridge the innovation gap between, on the one hand, early discoveries in tumour-immunology as well as in antibody technology and, on the other hand, the efficient translation and clinical validations of these findings in patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores